Literature DB >> 9767068

Pain in central and peripheral demyelinating disorders.

D E Moulin1.   

Abstract

Moderate to severe pain is a common feature of central and peripheral demyelinating disorders. Pain in multiple sclerosis tends to occur when the disease is well-established and usually lingers infinitely. Pain in Guillain-Barré syndrome tends to be particularly severe at the time of initial presentation and usually resolves over 8 to 12 weeks. Pain in both conditions is generally caused by either the direct effects of nerve injury or the result of paralysis and prolonged immobilization. Pain syndromes are well-defined in each disorder based on the underlying pathophysiology. Treatment involves a variety of pharmacologic and nonpharmacologic approaches individualized for each specific pain syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767068     DOI: 10.1016/s0733-8619(05)70103-1

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  16 in total

Review 1.  The role of sodium channels in chronic pain.

Authors:  Simon R Levinson; Songjiang Luo; Michael A Henry
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

2.  The impact of pain and other symptoms on quality of life in women with relapsing-remitting multiple sclerosis.

Authors:  Pamela K Newland; Robert T Naismith; Margaret Ullione
Journal:  J Neurosci Nurs       Date:  2009-12       Impact factor: 1.230

Review 3.  Pharmacological management of pain in patients with multiple sclerosis.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

4.  Transient receptor potential canonical 3 (TRPC3) is required for IgG immune complex-induced excitation of the rat dorsal root ganglion neurons.

Authors:  Lintao Qu; Yumei Li; Xinghua Pan; Pu Zhang; Robert H LaMotte; Chao Ma
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

5.  Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids.

Authors:  Victoria C J Wallace; David F Cottrell; Peter J Brophy; Susan M Fleetwood-Walker
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

Review 6.  Chemokines as pain mediators and modulators.

Authors:  Fletcher A White; Natalie M Wilson
Journal:  Curr Opin Anaesthesiol       Date:  2008-10       Impact factor: 2.706

Review 7.  Cytokine and chemokine regulation of sensory neuron function.

Authors:  Richard J Miller; Hosung Jung; Sonia K Bhangoo; Fletcher A White
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Willingness to pay for a treatment for pain in multiple sclerosis.

Authors:  Michael Iskedjian; Olivier Desjardins; Charles Piwko; Basil Bereza; Barbara Jaszewski; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada.

Authors:  Charles Piwko; Olivier B Desjardins; Basil G Bereza; Marcio Machado; Barbara Jaszewski; Mark S Freedman; Thomas R Einarson; Michael Iskedjian
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

Review 10.  Chemokines and the pathophysiology of neuropathic pain.

Authors:  Fletcher A White; Hosung Jung; Richard J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.